Loading clinical trials...
Loading clinical trials...
Comparative Risk Assessment of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants: A Network Study Across 4 US Observational Databases
Conditions
Interventions
Direct oral anticoagulant (DOACs)
Warfarin
Locations
1
United States
Janssen R&D
Titusville, New Jersey, United States
Start Date
May 15, 2020
Primary Completion Date
June 1, 2020
Completion Date
June 1, 2020
Last Updated
April 27, 2025
NCT02147197
NCT00350480
NCT01295294
NCT01254799
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions